- Home
- NBN vs GLUE Comparison
NBN vs GLUE Comparison
Compare NBN & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBN | GLUE |
|---|---|---|
| Founded | 1872 | 2019 |
| Country | United States | United States |
| Employees | 234 | 173 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NBN | GLUE |
|---|---|---|
| Price | $130.50 | $14.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $130.50 | $32.00 |
| AVG Volume (30 Days) | 99.6K | ★ 1.4M |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | $13.77 | N/A |
| Revenue Next Year | $18.72 | $2.45 |
| P/E Ratio | ★ $11.29 | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $80.75 | $4.54 |
| 52 Week High | $142.31 | $25.77 |
Technical Indicators
Market Signals| Indicator | NBN | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 29.77 |
| Support Level | $127.84 | $14.35 |
| Resistance Level | $137.75 | $14.62 |
| Average True Range (ATR) | 2.97 | 0.72 |
| MACD | -0.49 | -0.08 |
| Stochastic Oscillator | 23.82 | 0.80 |
Price Performance
Historical ComparisonAbout NBN Northeast Bank
Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).